Crescent Pharma Limited has initiated a precautionary recall of its Ramipril 2.5mg capsules following the discovery of a packaging error that could pose risks to patients.The affected batch, numbered GR155023, may contain blister strips of the higher-strength 10mg formulation rather than the intended 2.5mg dose.Ramipril is commonly prescribed for managing high blood pressure, heart failure and kidney disease.The Medicines and Healthcare products Regulatory Agency (MHRA) has urged patients currently taking this medication to examine their packaging carefully.The affected batches may contain blister strips of a higher strength | GETTYThose who identify the affected batch should verify that the strength indicated on their carton corresponds with the blister strips contained within.The issue came to light after a healthcare professional discovered two blister strips of 10mg capsules inside what appeared to be a properly sealed carton of the 2.5mg product.Investigators have determined that both the lower and higher dose batches were produced at the same manufacturing facility.The mix-up is believed to have occurred during the carton packaging process.This represents a significant dosage discrepancy, with the erroneously included capsules containing four times the intended strength of the medication.Pharmacies and other healthcare providers have been instructed by the MHRA to cease dispensing the affected batch immediately and return the remaining stock to their suppliers.Dr Alison Cave, the MHRA’s Chief Safety Officer, has provided clear guidance for those who may be affected.”If the 2.5mg carton of Crescent Pharma Limited Ramipril contains blister strips that are labelled as Ramipril 10mg capsules, do not to take the medicine and contact your dispensing pharmacy,” she stated.Patients whose cartons contain correctly labelled 2.5mg blister strips need not take any action and should continue their treatment as normal.Dr Cave advised that batch numbers and expiry dates can be located on the outer carton packaging.Those with affected medication should bring the accompanying leaflet and any remaining capsules to their pharmacy or GP surgery.Patients who believe they may have inadvertently consumed the higher-strength capsules and are experiencing adverse effects should seek medical attention promptly.”Signs and symptoms may include feeling lightheaded, fainting or being fatigued, or altered kidney function and may be more serious for vulnerable patients,” Dr Cave warned.The mix-up may have occurred during the carton packaging process | GETTYShe stressed that a healthcare professional should evaluate any potential consequences of taking an elevated dose to establish whether further examination or testing is required.The MHRA has requested that any suspected adverse reactions be reported through its Yellow Card scheme, which monitors the safety of medicines across the United Kingdom.